Understanding Patterns of Fatigue in Health and Disease

Heart Failure Clinical Trial

— FATIGUE  

Official title:

Understanding Patterns of Fatigue in Health and Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05622669
• Other study ID #: 2-090-22
• Status: Active, not recruiting
• Start date: December 7, 2021
• Est. completion date: March 30, 2024

Study information

• Verified date: February 2024
• Source: University of Aberdeen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Fatigue is a common symptom and can be the most distressing symptom of a range of medical conditions. This Ecological Momentary Assessment study will investigate lived experiences of fatigue in detail in individuals with myeloma, long COVID, heart failure, and in healthy controls without fatigue.

Participants will wear ECG patches and wrist-worn sensors that measure heart rate variability, activity levels, posture, and other parameters. They will self-rate their levels of fatigue four times daily and on-demand (when fatigue levels are noticeably good or troublesome). They will participate in an end of study interview and will have an optional feedback session with a researcher to make sense of the data they have provided.

Description:

Fatigue can be the most disabling symptom experienced by patients with a wide range of diseases. In primary care, it is very challenging for clinicians to differentiate between physiological fatigue (i.e., "normal" tiredness associated with lifestyle factors) and fatigue caused by underlying pathology such as heart disease or cancer. Treatment of persistent fatigue is usually by trial-and-error without attention to personalized triggers or disparate fatigue mechanisms.

This feasibility study will investigate patient experiences of fatigue in depth, combining objective measures of sensed physiological parameters with patient reports and validated patient reported outcome measures. Patients will be recruited with three distinct clinical conditions: myeloma; long COVID; and heart failure. A healthy control group will also be recruited.

Participants will participate in a feasibility study with a longitudinal, Ecological Momentary Assessment (EMA) design, wearing sensors, and providing four times daily short self-reports of fatigue over a two-to-four week period (to be determined by the individual participant and their preferences and patterns of fatigue). They will complete validated fatigue, affect, and interoceptive awareness scores at baseline and at two weeks and participate in end of study telephone interviews with a Research Assistant.

Sensors will measure objective parameters including activity levels; heart rate; sleep; and posture (sitting/standing). Additional sensors ("beacons") will measure participant's movements and positioning within their own environment (position relative to the beacons - beacon location to be determined by participant placement); environmental temperature; noise and light levels.

Data will be analysed using multilevel modelling and Machine Learning to detect patterns in the fatigue experiences and to compare fatigue measurements within individuals; between individuals with the same clinical condition; and between groups of individuals with different clinical conditions/controls.

This feasibility study will provide data that helps to determine:

• The utility and usefulness of different sensed parameters in understanding the fatigue experience

• The practicality and acceptability of collecting the proposed sensed and self-reported data and recruitment and retention rates (to inform a larger study)

• Whether there might be meaningful differences in fatigue between individuals and groups of individuals with distinct medical conditions

• Whether there is scope for a larger study into clinical "phenotypes" of fatigue (distinct classes of fatigue that might vary according to different combinations of physiological signatures, different patient descriptions/language used to describe the experience, diurnal variation, etc.)

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: March 30, 2024
• Est. primary completion date: December 18, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• For all groups, participants will be included if they are willing to participate in intermittent ecological momentary assessments of fatigue, to wear an ECG patch, to provide questionnaire responses at baseline, and the end of the study, and to participate in an end of study interview.

Inclusion Criteria for Group A, individuals with myeloma

• A confirmed diagnosis of myeloma

• Has experienced fatigue that is perceived by the participant to be worse than "normal tiredness" and that they associate with myeloma or treatment for myeloma

Inclusion Criteria for Group B, heart failure

• A formal diagnosis of heart failure

• All stages of heart failure and all aetiologies and with no specific ejection fraction cut-off

• Has experienced fatigue that is perceived by the participant to be worse than "normal tiredness" and that they associate with their cardiac disease or its treatment

Inclusion Criteria for Group C, long COVID

• Experiencing fatigue that is perceived by the participant to be worse than "normal tiredness", with or without other physical or psychological symptoms that developed during or after an infection consistent with COVID-19

• The fatigue (plus or minus any other symptoms) has continued for greater or equal to 12 weeks, and is not explained by an alternative diagnosis

Inclusion criteria for Group D, control group

• Individuals aged 18 years or over without the disease conditions specified in Groups A to C

Exclusion Criteria:

• Exclusion Criteria Applying to all participants:

• Difficulty communicating in English

• Adults lacking capacity to consent

• Under 18 years of age

• Declines to participate

• Under investigation for or starting treatment for an endocrine, metabolic, or thyroid condition where the participant has not been established on a stable therapeutic dose of a licensed therapy for that condition

• A confirmed diagnosis of sleep apnoea or narcolepsy

• HADs depression and anxiety score at baseline greater than 8 on the depression questions, which might indicate untreated or undertreated depression

• Shift work that involves overnight working between the hours of 9pm and 9am

We will not exclude patient participants in groups A to C based on the type of prescribed medications that they are taking. Instead, this will be carefully documented.

For Group A, myeloma

• Uncontrolled hypercalcaemia

• Current or previous diagnosis of heart failure or long COVID

• An active primary cancer diagnosis other than myeloma Group B Heart Failure

• A current or previous diagnosis of myeloma or long COVID

• Active cancer Group C, long COVID

• A current or previous diagnosis of myeloma or heart failure

• Active cancer Group D, Control group

• Presence of myeloma or another active cancer, heart failure, or long COVID

• One or more chronic medical conditions which are unstable, poorly controlled, AND perceived by the individual to be causing fatigue

• Persistent or severe fatigue symptoms that are perceived by the individual to be worse than "normal tiredness"

• Taking sedating medications to manage anxiety or insomnia including but not limited to benzodiazepines or "Z" drugs, zopiclone, zolpidem, and others in this British National Formulary Class.

Related Conditions & MeSH terms

• Fatigue
• Heart Failure
• Long COVID
• Myeloma

Intervention

Other:
• Observational
Sensed and lived experience data from all groups without a specific behavioural or drug intervention

Locations

Country	Name	City	State
United Kingdom	University of Aberdeen	Aberdeen	UK

Sponsors (6)

Lead Sponsor	Collaborator
University of Aberdeen	Lancaster University, University College, London, University of Cambridge, University of Glasgow, University of Southampton

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cognitive and physical fatigue screen (zero to ten point rating)	Fatigue screen based on "state" items from the validated Mental and Physical State and Trait Energy and Fatigue Scale (O'Connor P. University of Georgia; 2006). Participants will self-report their fatigue at that moment (split into physical and cognitive/mental fatigue) on a 0-10 point numerical rating scale, anchored with "I feel no fatigue" = 0 and "strongest feeling of fatigue ever" = 10. Participants will be prompted to respond via an app four times daily and can also provide on-demand ratings when their fatigue levels are particularly problematic or when they are not experiencing problematic fatigue. Multilevel modelling will be conducted to identify changes in fatigue over time and to explore the relationships between self-reported fatigue scores and sleep, activity levels (step-count, posture, measured by wrist worn sensor), respiratory rate (measured by ECG patch), and heart rate variability (measured by ECG patch)	Two to four weeks (participant defined)
Primary	Lived experiences of fatigue interview	Qualitative data collected by an end of study interview according to a topic schedule	1 day (End of study interview)
Primary	Views and opinions about the sensing technologies interview	Qualitative data collected by an end of study interview according to a topic schedule	1 day (End of study interview)
Primary	Views and opinions about the trial methods and study participation interview	Qualitative data collected by an end of study interview according to a topic schedule	1 day (End of study interview)
Secondary	Drop-out rate	The proportion of participants who drop out of the study before the end of study interview	Participant-led study end date - two to four weeks